De

Neonatal Diagnostics Company InfanDx AG Appoints Dr. Gunter Weiss as COO

Retrieved on: 
Wednesday, August 4, 2021

Cologne, Germany, August 4, 2021 InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the appointment of Dr. Gunter Weiss as Chief Operating Officer (COO).

Key Points: 
  • Cologne, Germany, August 4, 2021 InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the appointment of Dr. Gunter Weiss as Chief Operating Officer (COO).
  • Dr. Weiss brings to InfanDx more than 15 years of experience in biomarker and IVD development for the European, US and Chinese market.
  • Dr. Weiss joins InfanDx from a position as Senior Vice President Product Development at Epigenomics AG (Berlin, Germany), where he headed the development of cancer-related diagnostic IVD products.
  • InfanDx AG is a privately held company focusing on the development and commercialization of novel diagnostic solutions for acute and critical care conditions in newborns.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Translate Bio, Inc. Merger

Retrieved on: 
Tuesday, August 3, 2021

announces that it is investigating Translate Bio, Inc. (Translate Bio) (NASDAQ GS: TBIO ) regarding possible breaches of fiduciary duties and other violations of law related to Translate Bios agreement to be acquired by Sanofi.

Key Points: 
  • announces that it is investigating Translate Bio, Inc. (Translate Bio) (NASDAQ GS: TBIO ) regarding possible breaches of fiduciary duties and other violations of law related to Translate Bios agreement to be acquired by Sanofi.
  • Under the terms of the agreement, Translate Bios shareholders will receive $38.00 in cash for each share of Translate Bio common stock they own.
  • To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-translate-bio-inc .
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .

Gelato Network Brings Automated Liquidity Management to Zerion’s 200,000+ Monthly Users

Retrieved on: 
Tuesday, August 3, 2021

G-UNI, an automated liquidity provision ERC-20 framework for Uniswap v3 , will allow Zerions 200,000+ monthly active users to have their Uniswap v3 positions managed automatically to maximize their returns.

Key Points: 
  • G-UNI, an automated liquidity provision ERC-20 framework for Uniswap v3 , will allow Zerions 200,000+ monthly active users to have their Uniswap v3 positions managed automatically to maximize their returns.
  • Gelato Network is thrilled to work alongside Zerion to offer automated smart contract services within their user-friendly DeFi management platform, said Hilmar Maximilian Orth, Legendary Member of Gelato Network.
  • Zerion is one of the most popular aggregators powering DeFi, powering over $750,000,000 in volume and garnering 200,000 monthly active users.
  • Zerions agile approach to DeFi allows users to trade all Ethereum-based assets without taking custody of its users' funds.

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

Retrieved on: 
Tuesday, August 3, 2021

DATAcc members, including Dr. Dan Karlin, Chief Medical Officer of MindMed, will meet for the rst time today, marking the launch of this collaborative community dedicated to realizing the full potential of digital health measurement as a powerful new tool to drive improvements in health outcomes, health economics, and health equity.

Key Points: 
  • DATAcc members, including Dr. Dan Karlin, Chief Medical Officer of MindMed, will meet for the rst time today, marking the launch of this collaborative community dedicated to realizing the full potential of digital health measurement as a powerful new tool to drive improvements in health outcomes, health economics, and health equity.
  • "DATAcc can advance efforts to build the science and evidence generation for all people by keeping health outcomes and health equity front and center."
  • Dr. Daniel Karlin, Chief Medical Officer of MindMed, added, "We are eager to advance the science of digital medicine through cooperation and collaboration.
  • MindMed is a clinical-stage biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental health.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Aquesta Financial Holdings, Inc. Merger

Retrieved on: 
Monday, August 2, 2021

announces that it is investigating Aquesta Financial Holdings, Inc. (Aquesta) (OTC: AQFH ) regarding possible breaches of fiduciary duties and other violations of law related to Aquestas agreement to be acquired by United Community Banks, Inc. (United) (NASDAQ GS: UCBI ).

Key Points: 
  • announces that it is investigating Aquesta Financial Holdings, Inc. (Aquesta) (OTC: AQFH ) regarding possible breaches of fiduciary duties and other violations of law related to Aquestas agreement to be acquired by United Community Banks, Inc. (United) (NASDAQ GS: UCBI ).
  • Under the terms of the agreement, Aquestas shareholders will receive either 0.6386 shares of United or $21.50 in cash for each share of Aquesta common stock they own.
  • To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-aquesta-financial-holdings-inc .
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Royal Financial, Inc. Merger

Retrieved on: 
Monday, August 2, 2021

announces that it is investigating Royal Financial, Inc. (Royal Financial) (OTC: RYFL ) regarding possible breaches of fiduciary duties and other violations of law related to Royal Financials agreement to be acquired by Finward Bancorp (Finward) (OTC: FNWD ).

Key Points: 
  • announces that it is investigating Royal Financial, Inc. (Royal Financial) (OTC: RYFL ) regarding possible breaches of fiduciary duties and other violations of law related to Royal Financials agreement to be acquired by Finward Bancorp (Finward) (OTC: FNWD ).
  • Under the terms of the agreement, Royal Financials shareholders will receive either 0.4609 shares of Finward or $20.14 in cash for each share of Royal Financial common stock they own.
  • To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-royal-financial-inc .
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .

BioNTech to Report Second Quarter Financial Results and Operational Update on August 9, 2021

Retrieved on: 
Monday, August 2, 2021

A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.

Key Points: 
  • A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.
  • Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
  • BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Misonix, Inc. Buyout

Retrieved on: 
Friday, July 30, 2021

WILMINGTON, Del., July 30, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A.

Key Points: 
  • WILMINGTON, Del., July 30, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A.
  • announces that it is investigating Misonix, Inc. (Misonix) (NASDAQ GM: MSON ) regarding possible breaches of fiduciary duties and other violations of law related to Misonixs agreement to be acquired by Bioventus Inc. (Bioventus) (NASDAQ GS: BVS ).
  • To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-misonix-inc .
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .

Compas Elevates Travis Scott to Lead Supplier Partner Team

Retrieved on: 
Monday, August 2, 2021

CHERRY HILL, N.J., Aug. 2, 2021 /PRNewswire-PRWeb/ -- Compas today announced the promotion of Travis Scott to VP, Supplier Partner Team.

Key Points: 
  • CHERRY HILL, N.J., Aug. 2, 2021 /PRNewswire-PRWeb/ -- Compas today announced the promotion of Travis Scott to VP, Supplier Partner Team.
  • He is also responsible for building more effective associations that increase the value of Compas to clients and its partners.
  • The Supplier Partner Team is a differentiator for Compas, as it is a team completely dedicated to dedicated to supporting suppliers to grow and evolve to be in the best position to successfully earn and maintain client business.
  • "Travis' natural talent for building relationships combined with his hard-earned business expertise made him a perfect fit for leadership of the Supplier Partner Team," said Nicole Woodland-De Van, President, Compas.

Bernstein Litowitz Berger & Grossmann LLP Announces Pendency and Proposed Settlement of Stockholder Class Action Involving Holders of GCI Liberty Inc. Series A Common Stock

Retrieved on: 
Monday, August 2, 2021

themselves and all others similarlysituated,

Key Points: 
  • themselves and all others similarlysituated,
    SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION, SETTLEMENT HEARING,
    All holders of GCI Liberty, Inc. ("GCI Liberty") Series A common stock as of December 18, 2020, the date of the consummation of the merger of GCI Liberty and a subsidiary of Liberty Broadband Corporation (the "Merger") (the "Settlement Class").1
    PLEASE READ THIS NOTICE CAREFULLY.
  • YOU ARE ALSO NOTIFIED that Plaintiffs in the Action, on behalf of themselves and the Settlement Class, have reached a proposed settlement of the Action for $110,000,000 in cash (the "Settlement").If approved by the Court, the Settlement will resolve all claims in the Action.
  • Eligible Class Members do not have to submit a claim form to receive a payment from the Settlement.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Settlement Administrator or Plaintiffs' Lead Counsel.